ALLMedicine™ Oropharyngeal Cancer Center

Feb 15th, 2021 - High-dose (HD) cisplatin remains the standard of care with chemoradiation for locally advanced oropharyngeal cancer (OPC). Cooperative group trials mandate bolus-HD (100 mg/m2 x 1 day, every three weeks) cisplatin administration at the beginning o...

Feb 12th, 2021 - This observational study aims to determine individual dental doses in oropharyngeal cancer (OPC) patients managed by intensity modulated radiation treatment (IMRT). OPC patients treated with IMRT had each tooth individually contoured on post-IMRT ...

Feb 4th, 2021 - The incidence of human papillomavirus (HPV)-related oropharyngeal cancer (OPC) has increased, and staging and optimal therapeutic approaches are challenging. A questionnaire survey was conducted to investigate the controversial treatment policy of...

Feb 2nd, 2021 - Patients with oral cavity cancer (OCC) and oropharyngeal cancer (OPC) are often seen with locoregionally advanced disease requiring complex multimodality treatments. These treatments may have detrimental effects on the oral microbiome, which is cr...

Jan 28th, 2021 - We evaluate the performance between the TNM-8 versus TNM-7 cN-classification and explore the relative prognostic contribution of radiologic extranodal extension (rENE) for HPV-negative oropharyngeal cancer (HPV-OPC). All HPV- OPC treated with IMRT...

Feb 15th, 2021 - High-dose (HD) cisplatin remains the standard of care with chemoradiation for locally advanced oropharyngeal cancer (OPC). Cooperative group trials mandate bolus-HD (100 mg/m2 x 1 day, every three weeks) cisplatin administration at the beginning o...

Feb 12th, 2021 - This observational study aims to determine individual dental doses in oropharyngeal cancer (OPC) patients managed by intensity modulated radiation treatment (IMRT). OPC patients treated with IMRT had each tooth individually contoured on post-IMRT ...

Feb 4th, 2021 - The incidence of human papillomavirus (HPV)-related oropharyngeal cancer (OPC) has increased, and staging and optimal therapeutic approaches are challenging. A questionnaire survey was conducted to investigate the controversial treatment policy of...

Feb 2nd, 2021 - Patients with oral cavity cancer (OCC) and oropharyngeal cancer (OPC) are often seen with locoregionally advanced disease requiring complex multimodality treatments. These treatments may have detrimental effects on the oral microbiome, which is cr...

Jan 28th, 2021 - We evaluate the performance between the TNM-8 versus TNM-7 cN-classification and explore the relative prognostic contribution of radiologic extranodal extension (rENE) for HPV-negative oropharyngeal cancer (HPV-OPC). All HPV- OPC treated with IMRT...

May 2nd, 2019 - Treatment deintensification for patients with p16+ oropharyngeal cancer (OPC) should occur only in the context of a clinical trial, according to a provisional clinical opinion released by the American Society of Clinical Oncology (ASCO). “The hypo.

Oct 3rd, 2018 - NEW YORK CITY -- Adding a tumor-specific vaccine to PD-1 checkpoint inhibition was safe and effective in HPV16-positive patients with recurrent or metastatic oropharyngeal cancer, a small phase II trial found. Among 24 patients treated with nivolu...

Oct 26th, 2017 - The risk of developing oropharyngeal cancer (OPC) related to oral human papillomavirus (HPV) infection is very low in the general population and even in people with specific behavioral risk factors, a new study suggests. "Oropharyngeal cancer has ...

Oct 26th, 2017 - The risk of developing oropharyngeal cancer (OPC) related to oral human papillomavirus (HPV) infection is very low in the general population and even in people with specific behavioral risk factors, a new study suggests. "Oropharyngeal cancer has ...

Oct 23rd, 2017 - Action Points Men who smoked and had five or more lifetime oral sex partners had the highest prevalence of oral oncogenic human papilloma virus (HPV) infection (14.9%). The study suggests that even though the prevalence of infection is higher in m...